ABLYNX'S ANTI-IL-6R NANOBODY, ALX-0061, SHOWS EXCELLENT 24 WEEK SAFETY AND EFFICACY RESULTS IN A PHASE II CLINICAL TRIAL IN RHEUMATOID ARTHRITIS

World News: . []

ACR20 ACR50 and ACR70 scores of up to 100 75 and 63 respectively Up to 75 of patients in DAS28 LINK  Attractive safety profile at all administered doses No LINK  antibodies detected No disease progression as determined by MRI ra...

More news and information about Ablynx

Published By:

Thomson Reuters: 06:30 GMT Wednesday 13th February 2013

Published: .

Search for other references to "ablynx" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us